Migdal Insurance & Financial Holdings Ltd. Alnylam Pharmaceuticals, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$128.63 - $176.89 $665,017 - $914,521	-5,170 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$126.83 - $175.69 $406,870 - $563,613	3,208 Added 163.51%	5,170 $730,000
Q4 2020 Feb 08, 2021	BUY	$122.97 - $147.0 $241,267 - $288,414	1,962 New	1,962 $255,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.2 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.21 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.43 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.33 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.26 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account